VALNEVA Stock: Significant Decline of 8.67% Over the Week Amidst a Tense Context
Over the past week, Valneva's stock experienced a significant correction, dropping 8.67% to close at 4.06 euros on Thursday, October 24. This decline occurred in a generally favorable market environment, with the CAC 40 and SBF 120 showing respective gains of 0.45% and 0.53% over the same period. The French biotech company, specializing in vaccines, thus moved against the Parisian market trend.
The stock price declined throughout the week, moving from 4.30 euros on Monday to 4.06 euros on Thursday, marking a drop of nearly nine percentage points. Trading volumes indicate sustained activity, with over 613,000 shares traded on Monday, October 13, and about 535,000 on Friday, October 17. This downward trend follows an otherwise largely positive annual performance, with the stock up 51.64% since the start of 2025. The stock now fluctuates between 4.02 euros and 4.30 euros, moving away from the annual high of 5.42 euros reached earlier in 2025. Recent stock market context was influenced by the announcement on October 6 of lowered financial forecasts for 2025, following the temporary suspension of the chikungunya vaccine in the United States. Concurrently, the company announced a new loan agreement with Pharmakon to refinance part of its debt. On September 30, Valneva had reported positive results concerning the long-term protection offered by its chikungunya vaccine, which was not enough to support the stock price amid the downward revision of annual targets.
Technical Analysis and Stock Behavior
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Technically, the stock is now slightly below its 50-day moving average of 4.29 euros, indicating a short-term momentum deterioration. The 200-day moving average, at 3.32 euros, remains significantly below the current price, reflecting a still positive underlying trend since the start of the year. The RSI indicator is at 20, a level indicating significant oversold conditions, usually seen after strong corrections. The MACD shows a slightly negative value at -0.02, confirming recent selling pressure on the stock. Bollinger Bands frame the price between 3.93 euros and 5.17 euros, with the stock currently trading in the lower part of this range. The one-month volatility stands at 16.12%, a high level reflecting the magnitude of recent price movements. The negative beta of -0.08 further indicates a lack of correlation between the stock's variations and those of the Paris market, a characteristic often observed in biotechnological stocks driven primarily by specific catalysts.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
